Happy Friday all,
Neuren Pharmaceuticals Ltd (ticker = NEU) just made an interesting announcement re their Phase 2 trial, viz;
- showing safe & efficacious result during the stage 2 trials;
- has orphan drug designation from US FDA
- targets an area of high (& urgent) unmet need, even though it only impacts a small global market (10 to 20,000 patients pa)
Clearly, there are parallels with this great biz ($1.6Bn market cap) and our "yet to be great biz", but holy moly the signs are positive given the facts & similarities.
Surely we must be close to a similar news announcement with our very own Prescient !!
Break out the popcorn, the FDA are getting busy....may we follow soon !!
Go Aussie pharma !!
Dr Y
PTX Media related, page-1613
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
